Does treatment with rosiglitazone result in improved pancreatic beta-cell function as compared to glimepiride in metformin treated diabetes type 2 patients?
Completed
- Conditions
- Diabetes mellitus type II (DM type II)Nutritional, Metabolic, EndocrineDiabetes mellitus
- Registration Number
- ISRCTN52245496
- Lead Sponsor
- Academic Medical Centre (AMC) (The Netherlands)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
1. Informed consent form signed
2. Type 2 diabetes patients, according to World Health Organization (WHO) criteria
3. Age 18 - 70 years
4. Use of metformin, at least 500 mg a day
5. HbA1c greater than 7.0% inclusive when on metformin alone, or greater than 6.5% when on combination therapy of metformin and a sulfonylurea derivative. Use of a sulfonylurea derivative is allowed, with a wash-out period of four weeks before the first assessments.
Exclusion Criteria
1. Established coronary heart disease
2. Previous use of a thiazolidinedione
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The peak insulin concentrations during the hyperglycaemic clamp protocol.
- Secondary Outcome Measures
Name Time Method o secondary outcome measures